EGFR-Targeted Nanoparticles for Treating Multi-Drug Resistant Cancer
Author Information
Author(s): Milane Lara, Duan Zhenfeng, Amiji Mansoor
Primary Institution: Northeastern University
Hypothesis
Can EGFR-targeted nanoparticles improve the treatment of multi-drug resistant cancer using paclitaxel and lonidamine?
Conclusion
The study found that EGFR-targeted nanoparticles significantly reduced tumor volume and were less toxic compared to traditional drug solutions.
Supporting Evidence
- The combination nanoparticles were the only treatment group that decreased tumor volume.
- Treatment with the EGFR-targeted nanoparticles was considerably less toxic than solution treatments.
- Nanoparticle treatment led to a decrease in the expression of hypoxic and MDR associated proteins.
Takeaway
Researchers created tiny particles that can deliver cancer drugs directly to tough tumors, helping to shrink them while causing less harm to the body.
Methodology
The study used an orthotopic model of MDR human breast cancer in nude mice to evaluate the efficacy and safety of the nanoparticles.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
Nude mice with orthotopic, multidrug resistant breast tumor xenografts.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website